{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T09:51:24Z","timestamp":1776505884217,"version":"3.51.2"},"reference-count":30,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney Blood Press Res"],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background\/Aims:&lt;\/i&gt;&lt;\/b&gt; Chronic hepatitis C (HCV) virus infection reactivates under immunosuppressive drugs and therefore has a negative impact on long-term survival of kidney transplant recipients. Treatment-induced clearance of hepatitis C virus (HCV) in kidney transplant candidates prevents virus reactivation after transplantation. Paritaprevir\/Ritonavir\/Ombitasvir with Dasabuvir (PrOD) represents a highly effective treatment regimen for HCV genotype 1 (GT1), also suitable for patients with end-stage renal disease (ESRD). Serious drug-drug interactions may represent a limiting factor of this regimen. The aim of this retrospective study was to evaluate safety, efficacy and drug-drug interactions management associated with PrOD treatment in the Czech real-world cohort. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; Emphasizing concomitant medication adjustment, we described the treatment course with PrOD regimen in 23 patients (4 with CKD4 and 19 on maintenance haemodialysis) infected with HCV GT1 (21 GT1b, 2 GT1a), 18 males and 5 females with an average age of 53.7 years. Six patients had compensated liver cirrhosis and 3 of them were liver transplant recipients. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; All 23 patients completed the 12-week treatment and achieved sustained virological response 12 weeks after the treatment (SVR12 rate 100%). None of the patients presented with a significant decrease in haemoglobin level, white blood cell and platelet count during the treatment period. The most frequent adverse events were nausea, hypotension, diarrhoea, and hyperkalemia. Four patients presented with a serious adverse event unrelated to the antiviral drugs (salmonellosis, non-functional kidney graft rejection, early gastric cancer, renal cyst infection, initiation of haemodialysis). Concomitant medication had to be modified with the treatment initiation in 10 out of 23 (43.5%) patients (calcium channel blockers, ACE inhibitors, statins, diuretics, tacrolimus); four patients required further adjustment of antihypertensive drugs or tacrolimus dosage on-treatment. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; PrOD regimen demonstrated an excellent efficacy and good tolerability. Both prospective adjustment of concomitant medication and further on-treatment adjustment allowed for a safe treatment course.<\/jats:p>","DOI":"10.1159\/000488965","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T21:01:54Z","timestamp":1523998914000},"page":"594-605","source":"Crossref","is-referenced-by-count":21,"title":["Paritaprevir\/Ritonavir\/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort"],"prefix":"10.1159","volume":"43","author":[{"given":"Jan","family":"Sperl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miluse","family":"Kreidlova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dusan","family":"Merta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klara","family":"Chmelova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Senkerikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sona","family":"Frankova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290123"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-017-1394-9"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000355615"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.10.018"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408921"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.10.005"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00998-15"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.078"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000454819"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12664"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.01.037"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.241.45"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S80226"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.nephro.2014.08.002"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005924"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.483"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultrasmedbio.2015.04.014"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.003"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i18.5496"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28782"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02170216"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001482"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.051"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.044"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00349-9"}],"container-title":["Kidney and Blood Pressure Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/488965","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/488965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:24:29Z","timestamp":1745425469000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000488965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000488965","archive":["Portico"],"relation":{},"ISSN":["1420-4096","1423-0143"],"issn-type":[{"value":"1420-4096","type":"print"},{"value":"1423-0143","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}